Please login to the form below

Not currently logged in
Email:
Password:

Trial failure for bintrafusp alfa casts doubt on GSK/Merck KGaA’s cancer alliance

Bispecific antibody fails in non-small cell lung cancer trial

Bintrafusp alfa – the novel immunotherapy at the centre of a major alliance between GlaxoSmithKline (GSK) and Merck KGaA – has failed in a late-stage trial in difficult-to-treat cancers.

GSK and Merck entered the partnership in 2019 to jointly develop and commercialise bintrafusp alfa – previously known as M7824. At the time, the deal was said to be worth $4.2bn (€3.7 billion or £3.2bn) to the Darmstadt-headquartered Merck.

That includes an upfront payment paid by GSK to Merck of €300m – although the €500m earmarked for a milestone payment triggered by data from the lung cancer programme will now be lost.

The phase 3 INTR@PID Lung 037 study evaluated bintrafusp alfa as a first-line treatment for patients with stage IV non-small cell lung cancer (NSCLC) that have high expression of PD-L1.

In a statement, Merck said that the study’s Independent Data Monitoring Committee (IDMC) recommended that the trial should be discontinued, as it is ‘unlikely’ to meet the co-primary endpoint of progression-free survival.

“We have pioneered the science behind bintrafusp alfa, and now through a strategic alliance, multiple non-correlated parallel hypotheses are being evaluated across numerous indications in our extensive INTR@PID clinical program,” said Danny Bar-Zohar, global head of development for the healthcare business of Merck.

“We remain committed to further evaluation of bintrafusp alfa, and this data from INTR@PID Lung 037 will provide important insights that may be applied to future studies,” he added.

Despite failing in NSCLC, bintrafusp alfa will continue to be evaluated in a number of additional clinical trials across a range of cancer types.

This includes assessing the drug’s benefit in biliary tract cancer (BTC) and cervical cancer – top-line results for the BTC study are planned to be published in Q1, according to Merck.

The German pharma company also recently initiated monotherapy studies in triple-negative breast cancer and in locally advanced/metastatic urothelial cancer.

Bintrafusp alfa is part of a new wave of bispecific antibodies that are currently being developed by a number of companies as potential successors to the PD-1/PD-L1 inhibitor class.

The molecule is designed to simultaneously target two immuno-suppressive pathways, transforming growth factor-β (TGF-β) trap and an anti-programmed cell death ligand-1 (PD-L1), that are commonly used by cancer cells to evade the immune system.

Although GSK has not issued a press release regarding the NSCLC trial failure, a company spokesperson told Endpoints News: “No additional safety signals were observed by the IDMC. Development continues for bintrafusp alfa in several additional cancer indications.”

Article by
Lucy Parsons

21st January 2021

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...
wearable health tech
A cultural shift in clinical research
Research organisations across the board are experimenting with new technologies...

Infographics